Treatment Center Outreach Toolkit

The PROVENGE® (sipuleucel-T) Patient Outreach Toolkit for Practices is designed to help PROVENGE-Certified Treatment Centers educate patients and provide information on how your practice and PROVENGE can help patients with advanced prostate cancer.

This digital kit will help you:

  • Reach out to patients with advanced prostate cancer and inform them that your practice provides PROVENGE; and encourage them to talk to your healthcare practitioners to find out if PROVENGE is an appropriate option for them
  • Educate patients on what PROVENGE is, how it works, and what to expect from treatment

The Patient Outreach Toolkit includes:

  • Patient education videos and information on understanding PROVENGE and preparing for PROVENGE treatment, including patient testimonials
  • Digital artwork including PROVENGE-Certified Treatment Center logos for your practice website to inform patients you are a certified facility
  • A patient email template announcing that you are a PROVENGE-Certified Treatment Center


INDICATION: PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION:
Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.

Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please click here for full Prescribing Information.

P-A-01.15-044.00